Originally Posted by Delphic Oracle
Perhaps you are imagining something else. Where do you get "narrow target window" from?
I think you may be conflating what I said about antiviral treatments for herpes and flu. That short window for treatment is based on those infections' incubation periods and time to onset of symptoms. I didn't mean the 24-48 hours was going to be exactly the same for COVID. I just meant the intervention has a window period early on in the infection.
Person is exposed and then contracts COVID. They see a medical provider who recognizes they have risk of severe disease but they are not yet ill or they are only mildly ill.
The provider enrolls them in the study explaining they might get the drug or a placebo. The drug is not otherwise widely available.